Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
15.5M
-
Shares change
-
-2.5M
-
Total reported value, excl. options
-
$124M
-
Value change
-
-$24.1M
-
Put/Call ratio
-
0.6
-
Number of buys
-
33
-
Number of sells
-
-60
-
Price
-
$8.03
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q2 2021
107 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q2 2021.
NextCure, Inc. - Common Stock (NXTC) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.5M shares
of 28M outstanding shares and own 55.17% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), BlackRock Inc. (1.2M shares), Canaan Partners X LLC (838K shares), VANGUARD GROUP INC (805K shares), CITADEL ADVISORS LLC (712K shares), MORGAN STANLEY (576K shares), Ikarian Capital, LLC (517K shares), FEDERATED HERMES, INC. (510K shares), and MILLENNIUM MANAGEMENT LLC (403K shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.